Apr. 29, 2025 — A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete ...

Lymphoma begins when healthy cells in the lymphatic system change and grow out of control. Because of their expression of cell membrane receptor 30 (CD30), classical Hodgkin lymphoma is also referred ...

of subcutaneous Keytruda given alone in relapsed or refractory classical Hodgkin lymphoma and relapsed or refractory primary mediastinal large B-cell lymphoma. Another phase 2 trial will gauge ...

Seagen has a long history in ADC development, claiming FDA approval for Adcetris (brentuximab vedotin) as a treatment for classical Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL ...

MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation 1) is a key mediator of the classical NF-κB signaling pathway ... DLBCL is the most common form of non-Hodgkin’s lymphoma (NHL). The ...

Dr. Andrew M. Evens breaks down what it means to be an adolescent or young adult with lymphoma and how treatment differs from ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

In the treatment of non-Hodgkin lymphoma with CD19 chimeric antigen receptor (CAR) T-cell therapy, baseline kidney function did not appear to be associated with an increased risk of developing ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Leukemia and lymphoma are cancers that affect white blood cells, but they are separate conditions. In some people, they can occur simultaneously. However, people with Hodgkin’s lymphoma are more ...